Artivion (AORT) Proxy filing summary
Event summary combining transcript, slides, and related documents.
Proxy filing summary
1 Apr, 2026Executive summary
The annual meeting will be held virtually on May 12, 2026, with voting on director elections, executive compensation, and auditor ratification.
Shareholders of record as of March 16, 2026, are eligible to vote; a majority of shares constitutes a quorum.
The Board recommends voting for all director nominees, executive compensation, and auditor ratification.
Proxy materials and the 2025 Annual Report are available online and by request.
Voting matters and shareholder proposals
Nine directors are nominated for election to serve until the next annual meeting.
Advisory (non-binding) vote on executive compensation (Say-on-Pay) is included.
Ratification of Ernst & Young LLP as independent auditor for fiscal 2026 is proposed.
Shareholder proposals for the 2027 meeting must be submitted by December 2, 2026, for inclusion.
Board of directors and corporate governance
Board consists of nine members, with 22.2% female and 11.1% racial diversity; average tenure is 11.5 years.
Eight of nine directors are independent under NYSE standards; CEO serves as Chairman.
Four standing committees: Audit, Compensation, Corporate Governance, and Innovation & Healthcare Compliance.
Lead Independent Director role fosters board independence; committee charters and governance documents are available online.
Latest events from Artivion
- Virtual annual meeting to vote on directors, executive pay, and auditor ratification.AORT
Proxy filing1 Apr 2026 - AMDS and On-X drive growth, with NEXUS acquisition and margin expansion on the horizon.AORT
Oppenheimer 36th Annual Healthcare MedTech & Services Conference17 Mar 2026 - Double-digit revenue and EBITDA growth in 2025 with strong 2026 outlook and clinical momentum.AORT
Q4 202512 Feb 2026 - Q2 revenue up 10% and adjusted EBITDA up 35%, with raised full-year guidance and improved liquidity.AORT
Q2 20242 Feb 2026 - Double-digit growth and margin expansion driven by innovation in aortic disease solutions.AORT
Canaccord Genuity 44th Annual Growth Conference & Private Company Showcase 20242 Feb 2026 - Q3 revenue up 10% and adjusted EBITDA up 28%, led by product and international growth.AORT
Q3 202415 Jan 2026 - AMDS and global expansion drive double-digit growth and margin gains through 2025.AORT
Stifel 2024 Healthcare Conference13 Jan 2026 - Q1 revenue up 2% (4% constant currency), guidance raised, and product growth outpaced services.AORT
Q1 202527 Dec 2025 - AMDS launch, On-X growth, and margin expansion drive a robust outlook amid minimal macro risks.AORT
Oppenheimer 35th Annual Health Care MedTech and Services Conference26 Dec 2025